Company ProfilePremium

Netcare Limited

Company Profile Analysis

Ticker: NTC.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Netcare Limited - Company showcase

Year Founded & Workforce

1996

18,000 Employees

Netcare Limited logo

Netcare Limited Employee Contacts

6 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Netcare Limited Overview

Netcare is South Africa's largest private hospital operator. In the Competition Commission's Health Market Inquiry, it held about 31% of private hospital beds and 33% of admissions on 2016 data. Its operations are entirely in South Africa. They form an integrated ecosystem of 49 acute hospitals, the country's largest private mental health network (Netcare Akeso), pre-hospital emergency services (Netcare 911), cancer care, primary and occupational healthcare (Netcare Medicross, Netcare Occupational Health), prepaid and gap-cover products (NetcarePlus), point-of-care diagnostics, nursing and paramedic education, and an equity-accounted renal dialysis joint venture (National Renal Care). After leaving the UK in 2018, the group has pursued a ten-year, three-phase strategy launched in 2018: digitisation, data/AI-driven care, and person-centred care. It completed an ecosystem-wide electronic medical record in 2024. Since FY2022 it has expanded EBITDA margins every year, and it returns surplus cash through dividends (50–70% of adjusted HEPS) and a buyback programme that started in September 2023. Founder-CEO Dr Richard Friedland retires on 31 December 2026 and will be succeeded by Melanie Da Costa.


Company's own description. In its FY2024 annual financial statements, Netcare describes itself as a leading provider of private healthcare services in South Africa. It provides acute services across a national hospital network and is the market leader in acute mental health. It also provides emergency, cancer care, diagnostic support, primary care and renal care services, plus occupational health and wellness. It aims to widen access to affordable care through NetcarePlus products and vouchers, and Netcare Education trains nurses and emergency medical personnel (S3, FY2024). The directors' report describes Netcare Limited as an investment holding company. Through subsidiaries, joint arrangements and associates in Southern Africa, it runs a private hospital group offering general, emergency and specialised care, with ancillary primary care, administration and logistics businesses (S3, FY2024).

Reporting structure. Netcare reports two segments:

  1. Hospital and emergency services. This is about 97.5% of FY2025 revenue. It is split into:

    • Hospital and pharmacy operations: the acute hospital network, day clinics and institutional pharmacies.

    • Non-acute services: Netcare 911, Netcare Akeso mental health clinics, Netcare Cancer Care, Netcare Diagnostics, NetcarePlus product and voucher sales, and (from June 2025) Quro Medical hospital-at-home.

  2. Primary Care. This is about 2.5% of FY2025 revenue. It covers Netcare Medicross primary healthcare and dental centres, employee health and wellness (Netcare Occupational Health), and administrative services to medical and dental practices.

Revenue model. Netcare does not report revenue split by product versus service. Its revenue recognition notes (S3, FY2024) show the following mechanics:

Hospital and pharmacy (about 90% of revenue): ward, theatre and equipment fees, plus pharmaceuticals and consumables used during treatment. Revenue is recognised over the patient's stay. Most is paid by third-party medical schemes under annually negotiated tariffs, including lower-tariff Designated Service Provider (DSP) and restricted-network contracts. Cost of goods sold was R6,965m in FY2025, or 26.4% of revenue. This shows that dispensed medicines and consumables are a large part of billed value.

Emergency services: recognised once a contract exists with the patient or next of kin. In an emergency, no contract exists at the time of service.

Mental health: contract-based per-patient revenue.

NetcarePlus: prepaid vouchers and procedures are recognised when redeemed. Gap cover products are underwritten by a third-party insurer (Hollard).

Netcare Diagnostics: fees for administrative and logistics services to a third-party pathology practice.

Cancer care: a substantial part is operating-lease rental of oncology assets.

Primary Care: practice administration fees and per-visit treatment revenue. Occupational health revenue is earned under corporate contracts.

Other income: property rental income from doctors' rooms, pharmacies and retail tenants on hospital sites. This was R454m in FY2025 (S2, segment note) and R435m in FY2024.

There is no subscription or licensing model of significance. NetcarePlus prepaid products and GapCare have subscription-like features but are not separately sized.

Value-chain position. Netcare is a provider. It owns most of its hospital real estate. Land and buildings had a carrying value of R11.2bn and an independent fair value of R22.2bn at 30 September 2024 (S3, FY2024). It does not employ most specialists. Under South African rules, specialists are independent practitioners who hold admission rights. Netcare employs nurses, pharmacists, paramedics and support staff. Upstream, it buys pharmaceuticals, consumables and medical equipment. Downstream, it is paid mainly by medical schemes (funders), with some out-of-pocket, corporate (occupational health) and public-sector or uninsured (NetcarePlus) revenue.

Customer types and end markets.

  • Insured private patients (medical scheme beneficiaries). This is the dominant group, in a market of about 9.17 million scheme beneficiaries in 2024.

  • Medical schemes and administrators as contracting counterparties (for example DSP networks).

  • Employers (occupational health contracts).

  • Employed but uninsured households (NetcarePlus).

  • Government, through emergency services and historic public-private partnerships. The Lesotho PPP was terminated in August 2021.

  • Independent specialists and GPs who choose where to admit patients.

Independent characterisation. Netcare is a mature, high-fixed-cost, volume-sensitive hospital operator in a concentrated but slow-growing insured market. Its earnings growth since FY2022 has come mostly from margin expansion and per-share accretion, not from volume:

  • Total paid patient days (PPD) grew only 0.7% in FY2025 and about 1.6% in FY2026.

  • Normalised EBITDA margin rose from 15.2% (FY2021) to 18.6% (FY2025), helped by digitisation savings and lower strategic and diesel costs.

  • About 10.4% of shares were repurchased between September 2023 and FY2025.

Its strategic distinctiveness rests on four things: an integrated multi-service ecosystem, the first fully implemented ecosystem-wide EMR in Africa, the only four private Level 1 trauma centres accredited by the Trauma Society of South Africa, and leadership in private mental health.

Strategy

Stated corporate strategy (paraphrased from S1/S2). Netcare is executing a ten-year strategy launched in 2018. Its stated aim is a lasting competitive advantage and becoming the provider of choice for patients, doctors and funders. The strategy is built around three global healthcare megatrends (customer centricity, digitisation, and data/AI-driven care) applied across Netcare's integrated ecosystem. Management describes the group as being in the "latter stages" of the journey. There are three overlapping phases:

  1. Digitally enabled: completed in 2024 with full EMR rollout. All operating costs are now in the hospital cost base.

  2. Data and AI driven: "well advanced". About 53GB of clinical data is generated daily. Real-time analytics support standardised clinical pathways. Examples include a predictive ICU sepsis algorithm and a patient-facing large language model (both described as firsts in Africa), plus planned generative AI tools for clinicians and research.

  3. Person-centred health and care: gives patients direct access to their health records and deepens engagement.

Strategic initiatives, last 24 months (Oct 2024 – Oct 2026)

Cost programmes. No named group-wide cost programme with a rand target was disclosed beyond the digitisation savings and environmental savings above. Strategic project operating costs were R23m in H1 FY2026 (R17m attributable to NetcarePlus), and strategic capex was R17m.

Management guidance (FY2026; S2, May 2026):

  • Revenue growth 4.0%–4.8% (originally 4%–5%, S22).

  • Acute PPD growth 0.3%–0.8% (originally 0.8%–1.5%).

  • Total PPD growth 1.1%–1.6% (originally 1.8%–2.4%). Business Day reported 1.1%–1.8%; the primary interim document states 1.1%–1.6% (S8 vs S2).

  • Further EBITDA margin expansion, higher earnings and higher ROIC.

  • Capex about R1.9bn, of which R566m is expansionary.

  • Dividends of 50%–70% of adjusted HEPS; buybacks to continue to be considered.

Medium-term financial targets. Netcare does not publish explicit multi-year revenue, margin or ROIC targets. Debt policy thresholds are net debt/EBITDA below 2.75x and EBITDA/net interest above 4.0x.

Products & Services

The company does not publish a priced product catalogue. Hospital pricing is set through annual tariff negotiations with medical schemes and is not disclosed. Facility counts below come from the FY2023 results presentation, the latest primary-source asset count found. A later third-party description and subsequent company commissioning announcements are noted where they differ.

Hospital and pharmacy operations (H&ES segment)

OfferingDescription / capabilitiesTarget customerLatest data pointPricing modelSource
Netcare Hospitals (acute network)49 acute hospitals with 9,903 beds (FY2023). A later third-party count shows 9,827 beds. Medical and surgical admissions; surgical cases bring in over 70% of revenue and about 51% of PPD. ICU and high-care capacity is used above 2019 levels.Medical scheme members, referring specialists, funders (DSP networks)FY2025: acute occupancy 65.0%; average length of stay 4.5 days. FY2026: about 66% occupancy expected.Per-diem ward, theatre and equipment fees plus medicines, under negotiated scheme tariffsS5; S23; S1; S8
Flagship trauma centresNetcare operates the only four Level 1 trauma facilities in the private sector accredited by the Trauma Society of South Africa. Netcare Christiaan Barnard Memorial Hospital received Level One accreditation (FY2023). Netcare Milpark Hospital runs a dedicated trauma programme.Trauma patients, EMS, fundersH1 FY2026Tariff-basedS2; S5
Stroke centresTwo Netcare hospitals accredited by the World Stroke Organization in FY2025, a first in Africa (34 facilities worldwide)Stroke patientsFY2025Tariff-basedS1
Netcare Alberton HospitalNew 427-bed hospital commissioned April 2022; traded above 80% occupancy in FY2022East Rand / Gauteng catchment2,022Tariff-basedS4
Netcare Pretoria East Hospital358-bed hospital; fire in Dec 2024; excluded from PPD metricsTshwane catchmentFY2025–26Tariff-basedS1; S2
Netcare Blaauwberg HospitalCertified as the first Green Hospital in Africa (reported May 2026)Cape Town catchmentH1 FY2026Tariff-basedS2
Day clinics12 day clinics (FY2023); 11 in a later third-party countDay-case surgeryFY2023Tariff / procedure-basedS5; S23
Institutional pharmaciesIn-hospital medicine supply, management and dispensingInpatientsOngoingSingle exit price plus dispensing fees (regulated; Netcare-specific figures not disclosed)S23
Bed optimisation programme29 beds converted to higher-acuity disciplines and 51 new beds added in existing hospitals (H1 FY2026); about 19–20 further beds in H2 FY2026—FY2026—S2; S8

Non-acute services (H&ES segment)

OfferingDescription / capabilitiesTarget customerLatest data pointPricing modelSource
Netcare 911Pre-hospital emergency medical services: 92 sites (FY2023); a later third-party count gives 93 bases, 240 ambulances and response vehicles, 4 helicopter ambulances, 5 fixed-wing aircraft and a National Emergency Operations Centre. Emergency line 082 911 and access via the Netcare App.Public, scheme members, corporatesFY2023 / laterFee-for-service billed after contractingS5; S23
Netcare AkesoLargest private mental health network: 14 hospitals and 1,007 beds (FY2023), plus Polokwane (87 beds, March 2026). Pipeline: Alberlito (80 beds, March 2027) and Montana (88 beds, now August 2027, previously October 2026). Includes dialectical behaviour therapy programmes.Psychiatric and substance-use patientsMental health occupancy 70.0% (H1 FY2026); about 72.7% expected for FY2026Per-diem / programme tariffsS5; S2; S8
Netcare Cancer Care8 radiation treatment centres and 8 haematology centres (FY2023); 9 radiation centres in a later count. Radiosurgery, radiotherapy, chemotherapy, bone-marrow transplant and robotic-assisted surgery. Aria oncology EMR.Oncology patients and oncologistsFY2023 / laterPart of revenue is operating-lease rental of oncology assetsS5; S1; S3
NetcarePlusProducts for the employed but under-insured: prepaid healthcare vouchers; prepaid procedures (general, gynaecological, orthopaedic, ENT); dental vouchers; GapCare (three gap-cover products underwritten by Hollard); accident and trauma cover; primary care insurance; baby care. Sold through retail, financial-services and broker channels.Uninsured / under-insured households; scheme members on network plansFY2025: strong sales growth in retail and corporate channels. H1 FY2026: R17m of strategic operating costs.Prepaid (revenue recognised at redemption); insurance premiums with a third-party underwriterS4; S1; S2; S3
Netcare DiagnosticsPoint-of-care testing (192 devices, FY2023; 130 blood-gas analysers in ICUs and high-care units, rolled out in 2022). Administrative and logistics support to Dr Esihle Nomlomo Inc, a Black female-owned pathology practice. Pathology available at 24 Medicross facilities, 8 with point-of-care testing (H1 FY2025).Inpatients, Medicross patientsH1 FY2025Service fees to the pathology practiceS4; S5; S10
Quro Medical (55.88%)Tech-enabled "hospital at home": remote clinical-grade monitoring of acutely ill patients at homeFunders, patientsAcquired June 2025; R14m revenue and R1m operating loss in its first monthsFunder reimbursement contractsS16
Wearable continuous monitoringPilot of clinical-grade wearables in general wards at a flagship facility. Monitors heart rate, respiratory rate, core temperature, oxygen saturation and continuous blood pressure, integrated with the EMR. Group-wide rollout depends on pilot results.InpatientsAnnounced Nov 2025; pilot under way H1 FY2026Embedded in the hospital cost base (no separate pricing disclosed)S1; S2
Netcare EducationFaculty of Nursing and Ancillary Healthcare; Faculty of Emergency and Critical Care. A leading private trainer of nursing and emergency medical personnel.Students, Netcare workforce pipelineOngoingTuition / internalS1; S19
Digital platformsCareOn EMR (hospitals, emergency), Aria (cancer), NephrOn (renal), Netcare App, appointmed. Analytics platform processing about 53GB of clinical data daily. Large language model for patient engagement (first hospital group in Africa to deploy one). Predictive sepsis algorithm in ICU.Clinicians, patients, fundersFY2025–H1 FY2026Internal enablerS1; S2

Primary Care segment

OfferingDescription / capabilitiesTarget customerLatest data pointPricing modelSource
Netcare Medicross63 family medical and dental centres (FY2023), some with day theatresFamilies, scheme members, cash patientsFY2023Per visit; administration fees to practicesS5; S3
Netcare Occupational HealthEmployee health and wellness, travel health, risk management. 33 contracts and 1,135 clients (FY2023); 47 contracts in a later third-party count. A large contract was not renewed in May 2025; two new contracts were added in H1 FY2026.EmployersH1 FY2026Contract-basedS5; S1; S2; S23
Practice administration servicesAdministrative services to medical and dental practicesIndependent practitionersOngoingFeesS3
Prime CureMedical centres; count in secondary sources only (5)Lower-income insured——S19 (secondary)

Equity-accounted joint venture

OfferingDescriptionLatest data pointSource
National Renal Care (NRC)Renal dialysis: 73 facilities and 996 stations (FY2023); 75 facilities and 1,013 stations in a later third-party count. NephrOn EMR.H1 FY2026: JV and associate earnings +50% to R45m, driven by NRCS5; S23; S2

Financial Narrative

All figures are ZAR millions unless stated. Sources: FY2021–FY2022 from S4; FY2023–FY2024 from S3; FY2025 from S2 (FY2025 comparatives) and S1. "Normalised" figures are company non-IFRS measures that exclude exceptional items.

Income statement

Notes:

  • FY2021 normalised revenue (R21,005m) and normalised EBITDA exclude Lesotho PPP-related items.

  • FY2025 reported EBITDA is higher than normalised because it includes a R62m net insurance gain on the Pretoria East claim. Other FY2025 exceptional items: a R61m impairment of an investment in an associate and a R2m property impairment.

  • FY2024 normalised EBITDA was R4,530m. The FY2024 results release said normalised EBITDA rose 10.1% from R4,115m.

Margins and growth (analyst-calculated unless marked "co.")

CAGRs, FY2021–FY2025 (four years):

  • Reported revenue: 5.6% a year (5.8% on the normalised FY2021 base).

  • Normalised EBITDA: 11.4% a year.

  • Adjusted HEPS: 19.4% a year.

  • Dividend per share: 25.7% a year (34c to 85c).

The FY2023 EBITDA margin of 17.4% is derived; the FY2023 presentation reported a 120bp improvement.

Balance sheet (at 30 September)

Balance sheet at 31 March 2026:

  • Total assets R29,383m; cash R1,985m.

  • Borrowings R8,092m (short-term R1,354m; long-term R6,738m).

  • Net debt excluding leases R6,107m; lease liabilities R5,569m.

  • Total equity R10,938m.

Debt is all unsecured: promissory notes and commercial paper of R7,033m and bank loans of R1,054m. No property, plant or equipment is pledged as security (S3, FY2024). On 24 April 2026 Netcare raised R800m of new 3-year and 5-year term loans at about 7.7%.

Cash flow

Notes:

  • Analyst FCF = cash generated from operations, less interest paid on debt, less interest paid on leases, less tax paid, less capex, less lease principal.

  • Netcare presents dividends paid inside operating cash flows.

  • The FY2022 treasury share purchases of R29m were for incentive schemes. The buyback programme began in September 2023.

  • Netcare reported R1.8bn returned to shareholders through dividends and buybacks in FY2025.

  • FY2026: R1.04bn was spent to repurchase 60.2m shares. H1 FY2026: dividends of R626m (ordinary and preference) and buybacks of R351m.

Ratios

Notes:

  • The company's EBITDA/net interest cover was 4.3x in H1 FY2025 and 4.6x in H1 FY2026.

  • A full cash conversion cycle cannot be calculated reliably from disclosed balances, because trade and other payables include accruals. Netcare does not publish one, so it is not publicly disclosed. Inventory was R520m at FY2025 against cost of goods sold of R6,965m, about 27 days.

  • The FY2023 presentation states debt policy thresholds of net debt/EBITDA below 2.75x and EBITDA/net interest above 4.0x.

Commentary on trends, inflections and drivers

Recovery phase (FY2021–FY2023). FY2021 was distorted by the second and third COVID-19 waves (Beta and Delta). Netcare estimated about R521m of COVID-specific costs in FY2021. Revenue fell 2.6% in FY2021, but EBITDA rose 33.3% on cost control. The fourth wave (Omicron) in early FY2022 was milder, and activity normalised from late January 2022. Total patient days rose 5.4% in FY2022, and acute occupancy climbed from 56.2% to 59.3%. FY2023 brought the main revenue step-up, +9.5% to R23,699m. Normalised EBITDA rose 17.7% despite heavy load-shedding and diesel costs.

Margin-led phase (FY2024–FY2026). From FY2024, volumes have been nearly flat:

  • Total PPD: +0.3% expected for FY2024, +0.7% in FY2025, about +1.6% in FY2026.

Margins and per-share returns kept improving. The drivers are:

  1. Pricing and mix: acute revenue per PPD +6.0% in FY2024 and +4.1% in H1 FY2026, even as lower-tariff DSP volume grew.

  2. Digitisation dividend: cumulative gross cash savings and cost avoidance of R705m since FY2022, against total investment of R670m (R320m capex plus R350m implementation opex). The expected IRR was raised from above 25% (FY2025, S1) to above 30% (H1 FY2026, S2).

  3. Falling strategic project costs: R249m in FY2022, R131m in FY2024, R56m in FY2025.

  4. Energy savings: lower diesel use and energy-efficiency savings (Phase 1 environmental programme: R1.5bn cumulative savings, IRR about 40%, S2).

  5. Lower cost of debt: 8.9% in H1 FY2025 and 8.2% in H1 FY2026.

  6. Buybacks: weighted shares fell from 1,330m (FY2023) to 1,224m (FY2025) and 1,191m (H1 FY2026). This is why adjusted HEPS (+20.7% in FY2025) grew much faster than profit after tax (+17.0%).

Cash. Cash generated from operations jumped 25% to R5,468m in FY2025, with conversion of 111.3%. H1 FY2026 cash generation was lower at R1,653m (H1 FY2025: R2,069m) because of working-capital outflows: trade payables fell from R4,263m to R3,731m and receivables rose to R4,321m. This seasonal or timing outflow, together with dividends and buybacks, lifted net debt to R6.1bn at March 2026. FY2026 cash conversion is a monitorable.

Leverage. Net debt excluding leases has stayed between R4.9bn and R6.1bn since FY2022. Bank-debt leverage remains low at 1.1–1.2x. Including R5.6bn of IFRS 16 lease liabilities, total debt-like obligations were about R11.7bn at March 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment / metricFY2021FY2022FY2023FY2024FY2025

Hospital & pharmacy operations revenue (ZAR Mn)

19,46519,73321,47222,80723,648

Non-acute services revenue (ZAR Mn)

1,1521,2911,5781,6992,047

Hospital & emergency services revenue (ZAR Mn)

20,61721,02423,05024,50625,695

Primary Care revenue (ZAR Mn)

595634663712662

Inter-segment elimination (ZAR Mn)

-12-22-14-16-13

Group revenue (ZAR Mn)

21,20021,63623,69925,20226,344

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Segment / metricFY2021FY2022FY2023FY2024FY2025

Hospital & pharmacy EBITDA (ZAR Mn)

3,0403,2113,6614,2284,451

Non-acute services EBITDA (ZAR Mn)

80111168115315

H&ES EBITDA (ZAR Mn)

3,1203,3223,8294,3434,766

Primary Care EBITDA (ZAR Mn)

124163161148162

Hospital & pharmacy operating profit (ZAR Mn)

2,1442,2822,6153,1613,370

Non-acute services operating profit (ZAR Mn)

-104-7226-63126

H&ES operating profit (ZAR Mn)

2,0402,2102,6413,0983,496

Primary Care operating profit (ZAR Mn)

3672756179

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Hospital & pharmacy EBITDA margin (%)

15.616.317.118.518.8

Non-acute services EBITDA margin (%)

6.98.610.66.815.4

H&ES EBITDA margin (%)

15.115.816.617.718.5

Primary Care EBITDA margin (%)

20.825.724.320.824.5

H&ES revenue growth YoY (%)

—2.09.66.34.9

Primary Care revenue growth YoY (%)

—6.64.67.4-7.0

H&ES share of group revenue (%)

97.397.297.397.297.5

Primary Care share of group revenue (%)

2.82.92.82.82.5

Segment Margins & Growth (%)

MetricH1 FY2025H1 FY2026Change (%)

Hospital & pharmacy revenue

11,41611,9214.4

Non-acute services revenue

9311,06214.1

H&ES revenue

12,34712,9835.2

H&ES normalised EBITDA

2,2662,4297.2

H&ES normalised EBITDA margin (%)

18.418.7

0.3 pts

H&ES operating profit

1,6241,7578.2

Primary Care revenue

337303-10.1

Primary Care EBITDA

8172-11.1

Primary Care operating profit

3929-25.6

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue, reported (ZAR Mn)

21,20021,63623,69925,20226,344

Revenue, company-normalised (ZAR Mn)

21,00521,63623,69925,20226,344

Gross profit (ZAR Mn)

10,45210,55111,76212,45613,094

Operating profit, reported (ZAR Mn)

2,0762,2822,7163,1593,575

Operating profit, normalised (ZAR Mn)

2,0252,293—3,1983,559

EBITDA, reported segment total (ZAR Mn)

3,2443,4853,9904,4914,928

EBITDA, normalised (ZAR Mn)

3,1933,4964,1154,5304,912

Finance costs (ZAR Mn)

9038851,0641,2691,218

Profit before tax (ZAR Mn)

1,1761,5341,8072,1382,523

Taxation (ZAR Mn)

416484471591713

Profit for the year (ZAR Mn)

7601,0501,3361,5471,810

Profit attributable to owners of parent (ZAR Mn)

7309751,2711,4361,681

Basic EPS (ZAR cents)

54.672.394.5110.4135.3

Diluted EPS (ZAR cents)

54.371.793.5108.9132.9

HEPS (ZAR cents)

61.574.0101.0113.0133.7

Adjusted HEPS (ZAR cents)

67.483.2105.7113.7137.2

Dividend per share, declared (ZAR cents)

34.050.065.070.085.0

Weighted average shares (millions)

1,3361,3381,3301,2791,224

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

49.348.849.649.449.7

Operating margin, reported (%)

9.810.511.512.513.6

Normalised EBITDA margin, co. (%)

15.216.217.418.018.6

Net margin, profit for year (%)

3.64.95.66.16.9

Revenue growth YoY, reported (%)

—2.19.56.34.5

Normalised EBITDA growth YoY (%)

—9.517.710.18.4

Adjusted HEPS growth YoY (%)

107.423.427.07.620.7

Effective tax rate (%)

35.431.626.127.628.3

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (ZAR Mn)

25,62126,27027,80328,39129,225

Property, plant & equipment (ZAR Mn)

12,91513,46913,88714,41315,009

Right-of-use assets (ZAR Mn)

3,6003,7704,0734,4184,308

Goodwill + intangible assets (ZAR Mn)

1,8061,8431,8731,9202,132

Cash & cash equivalents (ZAR Mn)

1,4561,4992,2791,8021,889

Short-term debt (ZAR Mn)

1,8511,1051,2491,603562

Long-term debt (ZAR Mn)

4,9365,2656,0575,5056,805

Total borrowings (ZAR Mn)

6,7876,3707,3067,1087,367

Net debt excl. IFRS 16 leases (ZAR Mn)

5,3314,8755,0285,3065,478

Lease liabilities, total (ZAR Mn)

4,0964,4884,9925,5415,598

Total shareholders' equity (ZAR Mn)

10,58910,94411,04110,97210,988

Equity attributable to owners of parent (ZAR Mn)

9,93310,24610,37610,28910,227

Treasury shares, carrying (ZAR Mn)

3,5573,5043,9264,3064,396

Working capital, current assets less current liabilities (ZAR Mn)

-27157825119857

Dividends & Capital Returns and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Cash generated from operations (ZAR Mn)

3,7943,9504,1354,3745,468

Net cash from operating activities, after interest, tax and dividends as presented (ZAR Mn)

2,3051,8841,8801,8692,447

Capex: PPE and intangible payments (ZAR Mn)

1,1441,3961,5071,5191,630

Lease principal repaid (ZAR Mn)

170177226258301

Analyst free cash flow (ZAR Mn)

1,0501,1101,0581,0621,603

Ordinary dividends paid to owners of parent (ZAR Mn)

0728808850957

Preference dividends paid (ZAR Mn)

3938506362

Treasury share purchases, incl. buybacks (ZAR Mn)

029510722855

Cash conversion ratio, co. (%)

118.8113.0100.596.5111.3

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, attributable profit / closing attributable equity (%)

7.39.512.214.016.4

ROA, profit for year / total assets (%)

3.04.04.85.46.2

ROIC, co.-reported (%)

7.98.8—11.712.6

Current ratio (x)

1.001.031.151.021.15

Gross debt / total equity (x)

0.640.580.660.650.67

Net debt excl. leases / EBITDA, co. (x)

1.71.41.21.21.1

Interest cover, operating profit / total finance costs incl. leases (x)

2.32.62.62.52.9

EBITDA / net interest, co. bank-debt basis (x)

4.14.54.5——

Asset turnover, revenue / total assets (x)

0.830.820.850.890.90

Trade receivable days, receivables / revenue × 365

56.055.554.657.156.0

Revenue by Region and Region Margins & Growth (%)

RegionFY2021FY2022FY2023FY2024FY2025

South Africa / Southern Africa revenue (ZAR Mn)

21,20021,63623,69925,20226,344

Revenue growth YoY (%)

—2.19.56.34.5

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Share price at 30 Sep (ZAR cents)

1,6201,3721,3501,5411,420

Dividend per share declared (ZAR cents)

3450657085

Dividend payout, % of adjusted HEPS

50.460.161.561.662.0

Treasury share purchases (ZAR Mn)

029510722855

Net debt excl. leases (ZAR Mn)

5,3314,8755,0285,3065,478

Valuation Multiples

MultipleNetcareBasis

Market capitalisation

About R22.4bn

1,166m × R19.22

P/E on FY2025 HEPS

14.4x

1922 / 133.7c

P/E on trailing adjusted HEPS (150.1c)

12.8x—

EV (including lease liabilities, preference shares, NCI)

About R34.9bn

Market cap + R6.1bn net debt + R5.6bn leases + R0.64bn preference + R0.14bn NCI

EV / trailing normalised EBITDA (R5,066m)

6.9x

Consistent with Halo's 6.9x (23 Jun 2026)

EV / trailing revenue (R26,948m)

1.3x—

P/B (equity attributable R10,155m)

2.2x—

Trailing dividend yield (49c + 44c)

4.8%—

Bucket Details

BucketUnder 1 year1–2 years2–3 years3–4 yearsOver 4 yearsTotal

Debt

19902,4841,8361,7001,8309,840

Lease payments

751689686644

9984 (4–5 years: 627; over 5 years: 9,357)

12,754

Analyst Conclusions

Management guidance (FY2026, as revised May 2026; S2; S8)

  • Revenue +4.0%–4.8%. The September 2026 update indicated about +4%, the low end.

  • Acute PPD +0.3%–0.8% (about +0.8% indicated); total PPD +1.1%–1.6% (about +1.6% indicated).

  • Normalised EBITDA margin above 18.6%.

  • Capex about R1.9bn (R566m expansionary).

  • Payout 50%–70% of adjusted HEPS.

  • Implied H2 FY2026 revenue (analyst-derived): about R14.1bn, roughly +3% on H2 FY2025 (R13.7bn), given H1 FY2026 revenue of R13.3bn and full-year growth of about 4%.

Consensus growth expectations. Detailed consensus EPS and revenue forecasts are not publicly available in verified form. Aggregator 12-month price targets cluster near R17.

Bull case

  1. Margin runway continues. Margins rose in every year from FY2022 to H1 FY2026 (16.2% to 18.8%). The data/AI phase, wearables and renewable energy (about 60% from March 2027) should add further operating leverage. The digitisation track record (R705m savings on R670m invested) gives credibility.

  2. Per-share compounding. With about 15% of the September 2023 share base repurchased by FY2026 (209.2m shares) and leverage at about 1.2x, buybacks plus a 4–5% dividend yield support double-digit per-share returns even with low single-digit revenue growth.

  3. Mental health and adjacent growth. Mental health PPD about +8% and occupancy about 73%, with 255 beds coming. Hospital-at-home and NetcarePlus widen the addressable market beyond static scheme membership.

Bear case

  1. Volume ceiling. Scheme beneficiaries grew only 0.45% in 2024. Funder solvency measures cut acute volumes in FY2026 and forced a guidance cut. Margin expansion cannot continue indefinitely without volume.

  2. Policy overhang. NHI is law. Its single-fund design, if implemented, could change tariff-setting and purchasing. Competition policy limits acquisition-led growth.

  3. Transition and capital-allocation risk. A founder-CEO of about 30 years is leaving. H1 FY2026 cash generation fell 20%. Net debt rose to R6.1bn because of buybacks and dividends. Valuation (about 6.9x EV/EBITDA, about 13x trailing P/E) is now above aggregator targets after a roughly 35% rerating.

Key catalysts and monitorables (next 12 months)

  • 23 Nov 2026: FY2026 results, final dividend and FY2027 guidance. Watch for H2 margin delivery and cash conversion recovery.

  • 1 Jan 2027: Da Costa becomes CEO. Watch strategy continuity and any capital-allocation changes.

  • Calendar 2027 scheme benefit designs and DSP network tenders.

  • Wind PPA commissioning (six hospitals from September 2026; 56 facilities from March 2027).

  • Wearables pilot outcome and rollout decision.

  • Akeso Alberlito opening (March 2027) and Montana timing (August 2027).

  • NHI litigation outcomes and any proclamation of NHI Act sections.

  • Remgro's strategy for Mediclinic SA and Life Healthcare's complementary-services expansion.

  • Continuation and pricing of buybacks, given the share price is above aggregator targets.

Analyst verdict

Netcare is a well-run, cash-generative incumbent in a structurally constrained market. The FY2021–FY2025 record shows management's ability to extract operating leverage from a near-static volume base:

  • Normalised EBITDA compounded at about 11% a year on revenue growth of about 6%.

  • Adjusted HEPS roughly doubled, from 67.4c to 137.2c.

  • ROIC improved from 7.9% to 12.6%.

These gains rest on concrete actions, not accounting. The digitisation programme has paid back its investment, energy initiatives have cut costs, and buybacks have been executed below the current price (average 1,338c to May 2026, against 1,922c in August 2026).

The constraint is volume. Medical scheme coverage is flat at about 9 million lives. Funders are tightening benefits to protect solvency. FY2026 acute PPD growth of about 0.8%, together with the May 2026 guidance cut, shows how quickly funder behaviour reaches Netcare's income statement. Future growth depends on three things: further margin gains (now from a high 18–19% base), niche capacity growth (mental health, higher-acuity beds), and new care models (hospital-at-home, NetcarePlus) that are still small.

The investment case therefore turns on durability rather than growth. Netcare should be able to sustain mid-single-digit revenue growth, modest margin gains and steady capital returns, giving low-teens per-share earnings growth while leverage stays near 1.2x. The main swing factors are policy (NHI), funder contracting, and how smoothly leadership passes from a founder-CEO to a long-serving insider. Da Costa's background in health policy and in the Akeso build-out fits the mental health and policy-engagement priorities. After a re-rating to about 13x trailing earnings and about 7x EV/EBITDA, the shares price in much of the margin story. Upside likely needs evidence of volume recovery or measurable AI-driven savings in FY2027. This assessment is for information only and is not investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundEducationSource

Dr Richard H. Friedland

Chief Executive Officer; executive director

Co-founded Netcare in 1996; has led the group for more than three decades. Retires from the Board on 31 Dec 2026. Strategic adviser on a consultancy basis from 1 Jan to 30 Jun 2027. Business Day reports he originally planned to step down in September 2024 but stayed on when the planned succession did not proceed.

—

S9; S2

Melanie S. Da Costa

CEO-designate from 1 Jun 2026; CEO from 1 Jan 2027. Previously Executive Director: Strategy and Health Policy.

Joined Netcare in 2006 to set up its Health Policy Unit. Led the Akeso acquisition and served as Akeso MD. Prescribed officer (FY2024).

Chartered Financial Analyst (CFA)

S9; S3

Keith N. Gibson

Chief Financial Officer; executive director

CFO through FY2021–H1 FY2026; supervises preparation of the financial statements

CA(SA)

S2; S3

T. Akaloo

Prescribed officer

——

S3, FY2024

C.E. Grindell

Prescribed officer

——

S3, FY2024

W.N. van der Merwe

Prescribed officer

——

S3, FY2024

E. Bock

Prescribed officer (part of FY2024)

——

S3, FY2024

J. du Plessis

Former prescribed officer

Resigned 30 Jun 2024; 1,164,090 Single Incentive Plan shares forfeited

—

S3, FY2024

C.M. Vikisi

Company Secretary

——

S2

Directors' Remuneration

ExecutiveGuaranteed packageBonus paid (for prior year)Total cashGrant-date fair value of deferred sharesTotal incl. deferred grant

R.H. Friedland (CEO)

12,0525,23017,28221,67538,957

K.N. Gibson (CFO)

7,2042,5629,76610,62020,386

M.S. Da Costa

5,2451,4686,7136,08212,795

C.E. Grindell

4,6151,3245,9395,48611,425

T. Akaloo

4,2561,0575,3134,3809,693

J. du Plessis (to 30 Jun 2024)

2,7952,2635,0589,38014,438

Board of Directors

DirectorRoleNotes

Alex Maditse

Independent non-executive Chair

Lead Independent Director from 29 Jul 2024; Chair after Mark Bower retired on 30 Sep 2024

R.H. Friedland

Executive director (CEO)

Retiring 31 Dec 2026

K.N. Gibson

Executive director (CFO)

—

L. Human

Independent non-executive

FY2024 fees R1,563k

I. Kirk

Independent non-executive

Appointed 1 Jan 2023; CA; joined Audit Committee Jul 2024

B. Mathe

Independent non-executive

Appointed with effect from 1 Oct 2025, after B. Bulo (former Audit Committee Chair) resigned on 30 Sep 2025.

N. Moholi

Independent non-executive

—

R. Phillips

Independent non-executive

—

L. Stephens

Independent non-executive

Appointed 1 Jan 2023; CA and chartered director; Audit and Remuneration committees

Major Shareholders

HolderStakeBasis / dateSource

Government Employees Pension Fund (via Public Investment Corporation)

22.58% (beneficial)

30 Sep 2024, net of treasury shares

S3

Public Investment Corporation (as investment manager)

17.18%

30 Sep 2024

S3

Public Investment Corporation

19.67%

2 Jul 2025 (Profile's Handbook)

S17

Fairtree Asset Management

7.55%

30 Sep 2024

S3

Templeton Asset Management

6.58%

30 Sep 2024

S3

Ninety One SA

5.06%

30 Sep 2024

S3

Competitive Landscape

Key Competitors

#CompetitorSegment(s) competedOwnershipLatest scale dataSource
1

Life Healthcare Group (JSE: LHC)

Acute hospitals, mental health, renal (incl. former Fresenius Medical Care SA renal business), complementary services

Listed

FY2025 (Sep YE): revenue from continuing operations R25.1bn (+6%); acute revenue R21.3bn; normalised EBITDA R3.8bn (+4.7%); NEPS 100.3c. H1 FY2026: revenue R12.42bn (+2.4%); normalised EBITDA R1.96bn (+5.2%).

S12

2

Mediclinic Southern Africa

Acute hospitals, day clinics, mental health, sub-acute; ER24 (EMS); Intercare (primary care)

100% Remgro since 1 Jul 2026

About 50 hospitals, 8,991 beds, 21,400+ employees (SA and Namibia). Purchase consideration US$947m.

S13

3

National Hospital Network (NHN)

Acute (association of independent hospitals contracting collectively)

Members independently owned

——
4

Lenmed Health

Acute hospitals

Private

——
5

Busamed

Acute hospitals

Private

——
6

Clinix Health Group

Acute hospitals (township and peri-urban)

Private

——
7

JMH Group

Acute hospitals (KwaZulu-Natal)

Private

——
8

Melomed

Acute hospitals (Western Cape)

Private

——
9

ER24 (Mediclinic)

Emergency medical services vs Netcare 911

Remgro

—

S13

10

Intercare (Mediclinic)

Primary care / day hospitals vs Medicross

Remgro

—

S13

11

Life Healthcare mental health and renal units

Mental health vs Akeso; renal vs NRC

Listed

Complementary services revenue R2.6bn (+24.7%, FY2025)

S12

12

Public sector hospitals

Uninsured market (relevant to NetcarePlus, NHI)

State

——

Peer Comparison

GroupShare of private beds (%)Share of private admissions (%)

Netcare

31.033.0

Mediclinic

26.828.6

Life Healthcare

25.328.5

Three groups combined

8387

Peer Comparison FY2025

MetricNetcare (FY2025, Sep YE)Life Healthcare (FY2025, Sep YE)Mediclinic Holdings (group, FY to Mar 2026)

Revenue

R26.3bn

R25.1bn (continuing operations)

US$5,356m adjusted (includes Swiss operations)

Revenue growth

+4.5%+6.0%

+11% (+5% in constant currency)

Normalised EBITDA

R4.91bn

R3.8bn

US$842m adjusted

EBITDA margin

18.6%

about 15.1% (analyst-derived)

15.7%

Earnings per share growth

Adjusted HEPS +20.7%

NEPS +10.1%

—

Company Snapshot

18,000

Employees

1996

Founded

SWOT Analysis

Strengths

  • Margin leadership and operating leverage. Normalised EBITDA margin rose from 15.2% (FY2021) to 18.6% (FY2025) and 18.8% (H1 FY2026). FY2025 operating profit grew 11.3% on revenue growth of 4.5% (2.5x operating leverage).
  • Proven digital returns. Digitisation savings of R705m since FY2022 exceed the R670m investment, with an expected IRR above 30%.
  • Scale and market position. Largest private group: 31% of beds and 33% of admissions in the HMI; 49 acute hospitals and about 9,900 beds.
  • Strong balance sheet and cash generation. Net debt/EBITDA 1.1x (FY2025); cash conversion 111.3%; R2.9bn of liquidity at FY2025 and R3.0bn at H1 FY2026.
  • Clinical differentiation that attracts doctors. All four private Level 1 trauma centres; net 117 specialists granted admission rights in FY2025.
  • Underappreciated property value. Land and buildings fair value of R22.2bn against R11.2bn carrying value (FY2024).
  • Shareholder returns. Dividend raised from 34c (FY2021) to 85c (FY2025); 209.2m shares repurchased since September 2023.

Weaknesses

  • Weak volume growth. Total PPD +0.7% in FY2025 and about +1.6% in FY2026; acute PPD about +0.8% in FY2026.
  • No geographic diversification. All operations are South African since the UK exit, which cost a R1,534m impairment in 2018.
  • Dependence on funders. FY2026 acute volumes were directly reduced by scheme benefit redesign, and guidance was cut in May 2026.
  • Primary Care fragility. Losing one contract cut segment revenue by 7.0% in FY2025.
  • Heavy lease obligations. R5.6bn of lease liabilities and R12.8bn of undiscounted lease payments, mostly beyond five years.
  • Earnings growth reliant on buybacks. FY2025 adjusted HEPS +20.7% against profit after tax +17.0%. The weighted share count fell 4.3%.
  • Weak H1 FY2026 cash generation. R1,653m against R2,069m in H1 FY2025 because of working-capital timing.

Opportunities

  • Mental health expansion. 255 new beds (Polokwane, Alberlito, Montana) into demand that pushed FY2026 occupancy to about 72.7%.
  • Data and AI monetisation. Wearables (potentially the largest deployment globally), sepsis prediction and generative AI could lower length of stay and complications.
  • Hospital-at-home (Quro). Supports value-based contracts with funders.
  • NetcarePlus. Products for the employed but uninsured, and GapCare to retain patients on network plans.
  • Renewable energy cost relief. About 60% renewable use from March 2027 if the wind PPA extension proceeds; Phase 1 delivered R1.5bn of savings.
  • Public-private partnership under universal health coverage. Netcare positions its national footprint as an asset for NHI-era contracting.

Threats

  • NHI. The Act was signed in May 2024. A single-fund model could reshape private funding. Sections are not yet in force and several legal challenges are under way.
  • Scheme solvency measures and down-trading. Network migration and tighter managed care hit acute volumes in calendar 2026.
  • Competitive pressure. Life Healthcare's growing complementary services (+24.7%) and Remgro's full ownership of Mediclinic SA.
  • Competition policy. HMI findings on concentration and its recommendation to review creeping mergers limit acquisition-led growth.
  • Infrastructure and operational risk. Electricity tariffs, the Pretoria East fire (December 2024), and municipal water and power reliability.
  • Leadership transition. The founder-CEO leaves after about 30 years, and an earlier succession attempt did not proceed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Mar 2025Voluntary H1 FY2025 trading update. 112.6m shares repurchased since Sep 2023. FY2025 revenue guidance 5%–6%; capex guidance R1.5bn. S11Set H1 expectations. Full-year revenue later came in below this range at 4.5%.
May 2025Large occupational health contract ended without renewal S1Primary Care revenue down through FY2026
19 May 2025H1 FY2025 results: revenue +5.3% to R12,677m; normalised EBITDA +8.3%; adjusted HEPS +20.0% to 58.8c; interim dividend 36c (+20%); R473m buybacks; R984m returned to shareholders S10Confirmed margin-led earnings growth
Jun 2025Quro Medical acquisition completed (55.88%) S16First hospital-at-home capability
30 Sep 2025FY2025 voluntary trading update. B. Bulo resigned from the Board; B. Mathe appointed from 1 Oct 2025. S11Governance change on the Audit Committee
20 Nov 2025FY2025 trading statement (EPS, HEPS and adjusted HEPS up) S11Pre-announcement
24 Nov 2025FY2025 results: revenue R26,344m (+4.5%); normalised EBITDA R4,912m (+8.4%); adjusted HEPS 137.2c (+20.7%); dividend 85c (+21.4%); ROIC 12.6%; cash conversion 111.3% S1Strongest earnings growth since the recovery years
24 Nov 2025Wearable monitoring rollout announced; FY2026 guidance of 4%–5% revenue growth S1; S22Innovation signal; modest growth outlook
1 Dec 2025Remgro and MSC announced a restructuring giving Remgro full ownership of Mediclinic Southern Africa S13Competitor ownership consolidation
Dec 2025FY2025 ESG report: first MSCI ESG "AAA" rating; SBTi validation; B-BBEE Level 3 for the fourth consecutive year S18ESG credentials
8 Jan 2026Lesotho High Court judgment in Netcare Hospitals (Pty) Ltd & 2 Others v Tsepong (Pty) Ltd (CCT/0079/2024) S20Legacy PPP litigation.
Jan 2026Several medical schemes changed benefit structures and plan designs, moved members to network options and tightened managed care S2Main headwind to acute volumes in FY2026
16 Mar 2026Netcare Akeso Polokwane (87 beds) commissioned S2Mental health capacity growth
24 Mar 2026Voluntary operational update (5 months): revenue +4.5%; slight EBITDA margin gain despite lower activity; 167.1m shares repurchased cumulatively. Ahead of an investor conference at Sun City. S11; S22Early warning of volume softness
24 Apr 2026Raised R800m of 3-year and 5-year term loans at about 7.7% S2Refinancing at lower cost
19 May 2026Melanie Da Costa named CEO-designate (from 1 Jun 2026) and CEO (from 1 Jan 2027). Friedland retires 31 Dec 2026. S9Resolves a long-running succession question
21 May 2026H1 FY2026 trading statement: EPS and HEPS expected up 18%–23% S24Pre-announcement
25 May 2026H1 FY2026 results: revenue +4.8% to R13,281m; normalised EBITDA +6.6% to R2,501m; margin 18.8%; adjusted HEPS +21.9% to 71.7c; interim dividend 44c (+22.2%); ROIC 12.4% S2Continued per-share growth
25 May 2026FY2026 guidance cut: revenue 4.0%–4.8%; acute PPD 0.3%–0.8% S2Shows exposure to funder behaviour
25 May 2026Akeso Montana deferred to Aug 2027 (from Oct 2026) S2Slower capacity additions
25 May 2026Netcare Blaauwberg certified Africa's first Green Hospital; 54 environmental awards since 2013; AEE 2025 Global Winner S2ESG milestones
25 May 2026Net 63 specialists granted admission rights in H1 FY2026 (117 in FY2025) S2; S1Doctor attraction is the main source of volume
1 Jun 2026Da Costa took up the CEO-designate role S9Leadership transition begins
1 Jul 2026Remgro completed its US$947m acquisition of full control of Mediclinic Southern Africa S13Main competitor now privately held by a long-term owner
13 Jul 2026Interim dividend of 44c paid S2Shareholder return
Sep 2026Wind PPA due to begin supplying six Eskom-supplied hospitals (actual start not confirmed in sources reviewed) S2Energy cost and ESG
30 Sep 2026FY2026 voluntary update: total PPD about +1.6%; acute PPD about +0.8%; mental health PPD about +8.2%; acute occupancy about 66%; mental health occupancy about 72.7%; H&ES revenue +4.2%; group revenue about +4%; normalised EBITDA margin expected above 18.6%; R1.04bn spent on 60.2m shares; 209.2m repurchased since Sep 2023 S8On track for revised guidance; revenue at the low end of the 4.0%–4.8% range
23 Nov 2026 (scheduled)FY2026 audited results S8Next major catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue, reported rose from ZAR 21,200 Mn in FY2021 to ZAR 26,344 Mn in FY2025.
Netcare Limited — Income Statement: Revenue & Gross Profit
Series (ZAR Mn)FY2021FY2022FY2023FY2024FY2025
Revenue, reported21,20021,63623,69925,20226,344
Revenue, company-normalised21,00521,63623,69925,20226,344
Gross profit10,45210,55111,76212,45613,094

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Netcare, "Results for the year ended 30 September 2025" (24 Nov 2025)
  2. S2Netcare, Unaudited Interim Group Results for the six months ended 31 March 2026 (JSE SENS PDF) · SENS summary via ShareData · FilingReader summary (25 May 2026)
  3. S3Netcare, Audited Consolidated and Separate AFS, year ended 30 September 2024
  4. S4Netcare, Summarised Audited Group Results, year ended 30 September 2022
  5. S5Netcare, FY2023 results presentation and booklet
  6. S6Netcare, "Results for the year ended 30 September 2024" (25 Nov 2024) · SENS
  7. S7Netcare FY2021 results release (22 Nov 2021) · SENS
  8. S8Business Day, "Netcare on track for full-year guidance amid rising demand" (30 Sep 2026)
  9. S9Netcare, "Netcare appoints Melanie Da Costa as Chief Executive Officer" · Business Day (19 May 2026)
  10. S10Netcare H1 FY2025 interim results · release
  11. S11Netcare SENS voluntary updates: (28 Mar 2025); (30 Sep 2025); (24 Mar 2026); (30 Sep 2024) · sharedata.co.za · sharedata.co.za · sharedata.co.za
  12. S12Life Healthcare FY2025 media release (27 Nov 2025) · BizNews · Daily Investor (Life H1 FY2026)
  13. S13BusinessTech (Remgro takes control of Mediclinic SA) · Remgro SENS (29 May 2026) · Daily Investor · Cape Town ETC
  14. S14PMG briefing on HMI · Moonstone · Business Day (30 Sep 2019)
  15. S15IOL (CMS 2024 industry report) · Moonstone/Alexforbes · Business Report (2022 data)
  16. S16Launch Base Africa, Quro Medical acquisition (16 Dec 2025)
  17. S17Profile's Stock Exchange Handbook 2026 Issue 1 · 2025 Issue 3 · Google Finance (NTC:JSE) · Investing.com · Simply Wall St · Halo Technologies
  18. S18Netcare ESG Report 2025 summary · Shareholder Report 2025 summary · Sustainalytics · Netcare ESG 2025 PDF
  19. S19Apax/Netcare GHG release (25 Apr 2006) · Fin24 (28 Mar 2018) · SENS (14 May 2018) · Netcare Akeso Tribunal release · MLex · Wikipedia (secondary)
  20. S20Netcare Hospitals v Compensation Fund [2024] ZAGPPHC 1213 · LesothoLII (Jan 2026) · Hospersa (2014)
  21. S21Cape Argus / Pretoria News (Dec 2024)
  22. S22Business Day (24 Nov 2025) · Business Day (24 Mar 2026) · EWN (25 Nov 2024) · Business Report (25 May 2026)
  23. S23roic.ai company profile · Eulerpool
  24. S24Daily Investor (H1 FY2026 trading statement) · Daily Investor (H1 FY2025, NHI)

End of dossier.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.